Wedge Capital Management L L P NC Sells 2,730 Shares of McKesson Corporation $MCK

Wedge Capital Management L L P NC decreased its holdings in shares of McKesson Corporation (NYSE:MCK) by 7.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,384 shares of the company’s stock after selling 2,730 shares during the quarter. Wedge Capital Management L L P NC’s holdings in McKesson were worth $27,385,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of MCK. Norges Bank acquired a new stake in McKesson during the 2nd quarter worth $1,346,661,000. Alliancebernstein L.P. lifted its stake in shares of McKesson by 150.4% in the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock valued at $1,661,956,000 after purchasing an additional 1,362,386 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of McKesson by 56.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock worth $906,109,000 after purchasing an additional 446,060 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of McKesson by 45.6% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock worth $610,977,000 after purchasing an additional 261,296 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in shares of McKesson by 34.1% during the second quarter. The Manufacturers Life Insurance Company now owns 839,690 shares of the company’s stock worth $615,305,000 after purchasing an additional 213,406 shares during the period. 85.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on MCK. Weiss Ratings lowered McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research note on Thursday, February 5th. Robert W. Baird set a $968.00 target price on McKesson in a research report on Wednesday, January 14th. Leerink Partners reiterated an “outperform” rating and issued a $1,085.00 price target on shares of McKesson in a research report on Thursday, March 5th. Raymond James Financial set a $970.00 price objective on shares of McKesson in a research note on Thursday, March 5th. Finally, Barclays boosted their price objective on shares of McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Thirteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, McKesson has a consensus rating of “Moderate Buy” and an average target price of $960.93.

Insider Activity at McKesson

In related news, Director Maria Martinez sold 349 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the completion of the transaction, the director directly owned 301 shares of the company’s stock, valued at approximately $282,900.87. This represents a 53.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Leann B. Smith sold 190 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the transaction, the executive vice president owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This trade represents a 5.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,868 shares of company stock valued at $3,743,820 over the last three months. Insiders own 0.08% of the company’s stock.

McKesson Trading Down 0.4%

NYSE:MCK opened at $860.41 on Friday. McKesson Corporation has a 1 year low of $637.00 and a 1 year high of $999.00. The stock has a 50-day moving average price of $907.62 and a two-hundred day moving average price of $838.81. The stock has a market cap of $105.39 billion, a price-to-earnings ratio of 24.75, a PEG ratio of 1.39 and a beta of 0.38.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. During the same quarter in the previous year, the business posted $8.03 EPS. McKesson’s revenue for the quarter was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Sell-side analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio is 9.43%.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.